{"id":390829,"date":"2017-11-30T00:00:00","date_gmt":"2017-11-30T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0034-2017-biopharma-narcolepsy-treatment-algorithms-claims-data-analysis-us\/"},"modified":"2026-03-31T10:49:26","modified_gmt":"2026-03-31T10:49:26","slug":"algocg0034-2017-biopharma-narcolepsy-treatment-algorithms-claims-data-analysis-us","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/algocg0034-2017-biopharma-narcolepsy-treatment-algorithms-claims-data-analysis-us\/","title":{"rendered":"Narcolepsy | Treatment Algorithms | Claims Data Analysis | US"},"content":{"rendered":"<p>A number\u00a0of therapies from a range of drug classes are available to address the symptoms of narcolepsy including excessive daytime sleepiness and cataplexy. \u00a0Our Treatment Algorithms research leverages national patient-level claims data to explore the use of key therapies in narcolepsy, such as modafinil, armodafinil, and Xyrem,\u00a0in both newly diagnosed and recently-treated patients. These data provide important information regarding the patient journey in narcolepsy\u00a0including\u00a0treatment duration, switch patterns, and persistence and compliance by drug.<\/p>\n<p><strong>QUESTIONS ANSWERED<\/strong><\/p>\n<ul>\n<li>What patient share do key therapies and brands garner by line of therapy in newly diagnosed narcolepsy patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed narcolepsy patients?<\/li>\n<li>Where has Xyrem\u00a0been integrated into the treatment algorithm?<\/li>\n<li>What proportion of narcolepsy patients receive drug therapy within a year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within a year of diagnosis?<\/li>\n<li>What percentage of narcolepsy patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?<\/li>\n<li>What are the product-level compliance and persistency rates among drug-treated patients with narcolepsy?<\/li>\n<\/ul>\n<p><strong>PRODUCT DESCRIPTION <\/strong><\/p>\n<p>Treatment Algorithms: Claims Data Analysis: Provides detailed analysis of brand usage across different lines of therapy using real-world data patient-level claims data so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.<\/p>\n","protected":false},"template":"","class_list":["post-390829","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-narcolepsy","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390829","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390829\/revisions"}],"predecessor-version":[{"id":393953,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390829\/revisions\/393953"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390829"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}